April 5, 2019 — Medical device startup HeartHero was the winner in the Innovation Challenge at the 2019 American College ...
Diagnostic and Interventional Cardiology DAIC
Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.
April 05, 2019
April 5, 2019 — Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) ...
April 05, 2019
April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut ...
April 03, 2019
April 3, 2019 — The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral ...
April 03, 2019
April 3, 2019 — The U.S. Food and Drug Administration (FDA) recently cleared Bard Peripheral Vascular's Venovo Venous ...
April 03, 2019
April 3, 2019 — Essential Medical Inc. received U.S. Food and Drug Administration (FDA) clearance for its large bore ...
April 03, 2019
April 2, 2019 — A Swedish review of out-of-hospital cardiac arrest data shows rates of bystander cardiopulmonary ...
April 02, 2019
April 1, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) maga ...
April 01, 2019
March 29, 2019 — The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of ...
March 29, 2019
Feature | Structural Heart | Jeff Zagoudis
Structural heart interventions represent one of the fastest growing segments of cardiology, as the number of devices to ...
March 28, 2019
Interview with Frederick Masoudi, M.D., FACC, FAHA, professor of cardiology at the University of Colorado Hospital, and ...
March 28, 2019
March 27, 2019 — Training interventional radiologists to perform endovascular thrombectomies results in positive ...
March 27, 2019![New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.](/sites/default/files/styles/content_feed_medium/public/Entresto_bottles.jpg?itok=sp56E5GI)
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril ...
March 27, 2019
March 27. 2019 — A newly released expert consensus statement provides recommendations for the safe and effective ...
March 27, 2019
March 27, 2019 — The Centers for Medicare and Medicaid Services (CMS) proposed to update its national coverage policy ...
March 27, 2019